These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24937470)

  • 1. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure.
    Shi M; Shtraizent N; Polotskaia A; Bargonetti J; Matsui H
    PLoS One; 2014; 9(6):e99351. PubMed ID: 24937470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
    Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
    Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
    Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
    Liang Y; Besch-Williford C; Hyder SM
    Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β.
    Takahashi RU; Takeshita F; Honma K; Ono M; Kato K; Ochiya T
    Sci Rep; 2013; 3():2474. PubMed ID: 23959174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
    Polotskaia A; Xiao G; Reynoso K; Martin C; Qiu WG; Hendrickson RC; Bargonetti J
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1220-9. PubMed ID: 25733866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
    Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
    Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Kong Y; Brown ML; Bae I
    Oncotarget; 2013 Jul; 4(7):984-94. PubMed ID: 23846322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
    Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
    Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
    Loo LWM; Gao C; Shvetsov YB; Okoro DR; Hernandez BY; Bargonetti J
    Breast Cancer Res Treat; 2019 Feb; 174(1):257-269. PubMed ID: 30470976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ.
    Escoll M; Gargini R; Cuadrado A; Anton IM; Wandosell F
    Oncogene; 2017 Jun; 36(25):3515-3527. PubMed ID: 28166194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.
    Kollareddy M; Dimitrova E; Vallabhaneni KC; Chan A; Le T; Chauhan KM; Carrero ZI; Ramakrishnan G; Watabe K; Haupt Y; Haupt S; Pochampally R; Boss GR; Romero DG; Radu CG; Martinez LA
    Nat Commun; 2015 Jun; 6():7389. PubMed ID: 26067754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
    Xiao G; Annor GK; Fung K; Keinänen O; Zeglis BM; Bargonetti J
    Mol Pharm; 2021 Jan; 18(1):338-346. PubMed ID: 33289569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
    Cuddihy AR; Jalali F; Coackley C; Bristow RG
    Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.
    Bristow RG; Peacock J; Jang A; Kim J; Hill RP; Benchimol S
    Oncogene; 2003 May; 22(19):2960-6. PubMed ID: 12771947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246.
    Zhou X; Santos GS; Zhan Y; Oliveira MMS; Rezaei S; Singh M; Peuget S; Westerberg LS; Johnsen JI; Selivanova G
    Br J Cancer; 2022 Nov; 127(11):2060-2071. PubMed ID: 36138076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expressions and significance of TIMP-3 and mtp53 in non-small cell lung cancer].
    Yang H; Li J; Guo J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2012 Apr; 15(4):202-7. PubMed ID: 22510504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN.
    Ellison V; Polotskaia A; Xiao G; Leybengrub P; Qiu W; Lee R; Hendrickson R; Hu W; Bargonetti J
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer.
    Berke TP; Slight SH; Hyder SM
    Onco Targets Ther; 2022; 15():23-30. PubMed ID: 35035222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.